UNSPSC 51432703: Zabiciprilat

This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A2D355316. European Medicines Agency schedules Zabiciprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00126MIG. Zabiciprilat generally arises in the molecular formula C21H28N2O5.

UNSPSC 51432703 Zabiciprilat is a Commodity code covering pharmaceutical products supplied to state and local health systems, emergency response agencies, and pharmacy benefit programs. State and local governments procure this medication and similar advanced life support pharmaceuticals for emergency medical services, hospital formularies, and managed health plans. Recent opportunities show solicitations for single-unit and bulk-quantity medications with strict expiration-date and quality-assurance requirements, delivered to specific jurisdictions or distributed through authorized wholesaler networks. Issuing bodies include city fire rescue departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The code reflects working procurement of branded and generic pharmaceuticals where vendors must demonstrate regulatory compliance (FDA approval, cGMP certification, Drug Supply Chain Security Act compliance), provide comprehensive product documentation and Safety Data Sheets, and often meet accessibility standards for digital submissions.

Activity appears concentrated in Texas and Minnesota, with recent solicitations from the City of Tampa, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue with a due date of April 8, 2026 and an estimated contract value of $40,000. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products across state and local facilities in Minnesota and Oregon with proposals due March 26, 2026, requiring vendors to maintain relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson. The Texas HHS Commission posted RFI HHS0017013 on March 27, 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for a future Therapeutic Pharmacy Initiative, signaling evolving procurement strategy in that state. MMCAP's two-year contract framework and the City of Tampa's one-year base with optional renewals reflect typical state and local pharmaceutical supply agreements.